Analyst Price Targets — MYGN
Latest News for MYGN
Piper Sandler cuts Myriad Genetics stock to Underweight, citing doubts about the genetic testing company's path to sustainable profitability.
SALT LAKE CITY, Aug. 27, 2026 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in molecular diagnostic testing and precision medicine, today announces Myriad management will present at the 21st Annual Wells Fargo Healthcare Conference in Boston on Thursday, September 10, 2026 at 11:00am EST. The presentation will be available through a live audio webcast link in the investor information section of…
NEW YORK--(BUSINESS WIRE)---- $MYGN #classactionlawsuit--The law firm of Kirby McInerney LLP reminds investors of its investigation on behalf of Myriad Genetics, Inc. (“Myriad Genetics” or the “Company”) (NASDAQ: MYGN) investors concerning the Company's and/or members of its senior management's possible violation of the federal securities laws or other unlawful business practices. [LEARN MORE ABOUT THE…
Dimensional Fund Advisors LP trimmed its position in shares of Myriad Genetics, Inc. (NASDAQ: MYGN) by 42.6% during the first quarter, according to the company in its most recent Form 13F filing with the SEC. The institutional investor owned 739,051 shares of the company's stock after selling 548,396 shares during the quarter. Dimensional
Assenagon Asset Management S.A. decreased its holdings in Myriad Genetics, Inc. (NASDAQ: MYGN) by 28.7% during the undefined quarter, according to the company in its most recent disclosure with the SEC. The institutional investor owned 1,031,464 shares of the company's stock after selling 415,497 shares during the quarter. Assenagon Asset Management S.A. owned
🧮 Earnings Move Analyzer
Insider Trading
Insider Trading
| Name | Role | Date | Type | Shares | Price | Form | Link |
|---|
Senate Trading
No Senate trades found for MYGN.
U.S. House Trading
No House trades found for MYGN.
Options Chain
Select an expiration to expand. Bid/Ask are shown first (before Mark) on both sides.